Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Verizon (VZ) downgraded to Hold from Buy at Argus with analyst Joseph Bonner citing the company's subscriber losses and "intense competition." He says that the company has been forced to offer "unsubsidized phone plans and unlimited data" which have hurt its results. 2. Cabot Oil & Gas (COG) downgraded to Outperform from Strong Buy at Raymond Jame with analyst John Freeman citing recent outperformance and lower natural gas pricing forecasts. 3. Manhattan Associates (MANH) downgraded to Hold from Buy at Benchmark with analyst Mark Schappel noting that the company's cut to its 2017 revenue outlook was its third consecutive guide down. Schappel lowered his price target on Manhattan Associates shares to $48 from $65. 4. Humana (HUM) downgraded to Hold from Buy at Jefferies with analyst David Windley saying he views the as expensive and points out that 2018 premium growth under President Trump is lower than 2017 under Obama. 5. Plains All American (PAA) downgraded to Hold from Buy at Jefferies with analyst Christopher Sighinolf saying the valuation appears full at current share levels. The analyst lowered his price target for the name to $27 from $28. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

RBC Capital lowered the firm's price target on Humana to $353 from $415 but keeps an Outperform rating on the shares after its Q1 results and updated outlook. While the management is taking 2025 adjusted EPS growth targets off the table for now, the company also stressed its continued commitment to margin improvement next year, indicating that pulling guidance does not signal that 2025 is a no-growth year, the analyst tells investors in a research note. RBC adds however that it is still cutting its FY25 EPS outlook for Humana to $20.28 from $23.87.

Oppenheimer analyst Michael Wiederhorn lowered the firm's price target on Humana to $370 from $415 and keeps an Outperform rating on the shares. The firm says Humana handily topped Q1 2024 expectations and maintained FY2024 guidance, highlighted by improving IP trends in March, leading to an in-line MLR without any contribution from favorable Q4 PPRD that seems likely. Looking forward, management pulled its 2025 growth guidance of $6-$10 EPS due to the rate pressures and TBC limitations, and also extended its return to 3% margins beyond 2026, says Oppenheimer. Overall, Humana continues to face the magnified impact from MA due to its significant exposure, but also boasts a portfolio with significant long-term margin upside, the firm adds.

DA Davidson upgraded Manhattan Associates to Buy from Neutral with a price target of $240, up from $220. The stock correction this year is overdone, especially following a quarter where the company exceeded expectations and raised guidance, the analyst tells investors in a research note. The firm says the shares now trade below its three-year bottom quartile forward price-to-earnings ratio, "an attractive entry for buyers today." The firm believes Manhattan is a "definitive" return on invested capital leader and "deserves more recognition from the market." Manhattan "generates pre-tax return on invested capital of 135%, a number we had to triple-check and sanity-check with management," writes DA Davidson.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

Ribbon Communications (RRBN) announced plans for a major network modernization program with Verizon (VZ) to retire legacy TDM switching platforms and replace their function with modern cloud-based technologies. Verizon is leveraging Ribbon's portfolio of Voice Products including the vC20 Call Controller, G5 Line Access Gateway, G6 Universal Media Gateway, virtual and Cloud-native Session Border Controllers, and other products which allows for the consolidation and replacement of equipment with energy efficient, software-centric platforms while maintaining full feature functionality.

Affirms FY 2024 Insurance segment benefit ratio of approximately 90%. Raises 2024 individual Medicare Advantage annual membership growth by 50,000 to now anticipate annual growth of approximately 150,000, or 2.8%.

Reports Q1 revenue $29.61B, consensus $28.47B.